Researchers at the University of Arizona have uncovered a previously unknown population of circulating immune cells that play ...

Researchers discover circulating immune cells that drive fibrosis, revealing a new therapeutic target to prevent scar tissue ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

Pirfenidone, an oral antifibrotic, improves lung function and reduces acute pulmonary exacerbations in patients with grades 2-3 radiation induced lung injury.

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...

Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...

University of South Florida pulmonologist Dr. Jose Herazo-Maya has focused his career on researching treatments for pulmonary fibrosis, a devastating and deadly lung disease. Pulmonary fibrosis in ...